Trial Bank
35 trials match
- A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
MSProgressive MSPhase 2Recruiting
Sundance Biosciences, Inc. · 2026 · 20 participants
- ZB020-03-001: A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 3Recruiting
orelabrutinib · Zenas BioPharma (USA), LLC · 2026 · 705 participants
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
MSRelapsing and progressivePhase 4Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2025 · 60 participants
- FENtrepid: A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 3Running, not recruiting
fenebrutinib · Hoffmann-La Roche · 2020 · 985 participants
- GAVOTTE: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
MSProgressive MSPhase 3Running, not recruiting
methylprednisolone, ocrelizumab, terfenadine · Hoffmann-La Roche · 2020 · 769 participants
- 35RC21_9806: MAESTRO-4MS : "Allogenic Adipose tissue-derived Mesenchymal Stromal Cells for the treatment of Primary Progressive Multiple Sclerosis: an open-label phase I clinical trial."
MSProgressive MSPhase 1Recruiting
Centre Hospitalier Universitaire De Rennes · 2025 · 15 participants
- MAXIMS: Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis
MSProgressive MSPhase 3Suspended
masitinib · AB Science · 2022 · 800 participants
- O'HAND: A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 3Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2019 · 1,013 participants
- MuSicalE: Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis
MSRelapsing and progressiveCompleted
ocrelizumab · Hoffmann-La Roche · 2018 · 1,710 participants
- DUOC for MS: Intrathecal Administration of DUOC-01 in Adults With Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 1Completed
Joanne Kurtzberg, MD · 2021 · 20 participants
- PERSEUS: Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)
MSProgressive MSPhase 3Completed
tolebrutinib · Sanofi · 2020 · 767 participants
- MAESTRO-4MS: Allogenic Adipose Tissue-derived Mesenchymal Stromal Cells for the Treatment of Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 1Recruiting
Rennes University Hospital · 2025 · 10 participants
- AB20009: A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib Dose Titration to 4.5 mg/kg/day versus Placebo in the Treatment of Patients with Primary Progressive or Secondary Progressive Multiple Sclerosis Without Relapse
MSProgressive MSPhase 3Terminated
masitinib · Ab Science · 2024 · 145 participants
- FNO-RS2-OCREPRIPRO: The use of therapeutic monitoring of ocrelizumab serum concentrations for personalized pharmacotherapy of relapsing-remitting and primary progressive multiple sclerosis
MSRelapsing and progressivePhase 4Recruiting
ocrelizumab · Fakultni Nemocnice Ostrava · 2025 · 100 participants
- A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 1Not yet recruiting
busulfan · Stanford University · 2025 · 10 participants
- Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
MSRelapsing and progressivePhase 3Completed
ocrelizumab, terfenadine · Genentech, Inc. · 2016 · 131 participants
- Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study
MSProgressive MSCompleted
Duke University · 2013 · 28 participants
- Assessing the Role of Mitochondrial Dysfunction in Primary Progressive Multiple Sclerosis
MSRelapsing and progressiveStatus unknown
IRCCS San Raffaele · 2021 · 140 participants
- Gray Matter Demyelination in Primary Progressive MS at 7T
MSProgressive MSStatus unknown
Danish Research Centre for Magnetic Resonance · 2021 · 60 participants
- Oratorio: A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 3Completed
ocrelizumab · Hoffmann-La Roche · 2011 · 735 participants
- A phase 3 study to compare efficacy and safety of masitinib with placebo in the patients with primary progressive or secondary progressive multiple sclerosis without relapse.
MSProgressive MSPhase 3Ongoing
masitinib · AB Science · 2021 · 800 participants
- ARPEGGIO: A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
MSProgressive MSPhase 2Completed
laquinimod · Teva Branded Pharmaceutical Products R&D, Inc. · 2015 · 374 participants
- Hydroxychloroquine in Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 2Completed
hydroxychloroquine · University of Calgary · 2016 · 35 participants
- Idebenone for Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 1Phase 2Completed
idebenone · National Institute of Allergy and Infectious Diseases (NIAID) · 2013 · 61 participants
- FUMAPMS: Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 2Completed
dimethyl fumarate · Copenhagen University Hospital, Rigshospitalet · 2016 · 54 participants
- A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)
MSRelapsing and progressivePhase 3Completed
Genentech, Inc. · 2018 · 141 participants
- IPPoMS: Clinical Trial of Idebenone in Primary Progressive Multiple Sclerosis (IPPoMS)
MSProgressive MSPhase 1Phase 2Completed
idebenone · National Institute of Allergy and Infectious Diseases (NIAID) · 2009 · 85 participants
- Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis
MSProgressive MSPhase 2Completed
masitinib · AB Science · 2005 · 35 participants
- Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
MSProgressive MSNo longer available
ocrelizumab · Genentech, Inc.
- OLYMPUS: A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 2Phase 3Completed
rituximab · Genentech, Inc. · 2004 · 439 participants
- Hydroxyurea in Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 2Phase 3Terminated
hydroxyurea · S. Andrea Hospital · 2011 · 33 participants
- ND: An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis.
MSProgressive MSPhase 2Completed
naltrexone · OSPEDALE S. RAFFAELE · 2006 · 40 participants
- A pilot single-centre randomised controlled trial of recombinant human erythropoietin versus placebo in primary progressive multiple sclerosis.
MSProgressive MSPhase 2Terminated
epoetin beta · Walton Centre for Neurology and Neurosurgery · 2009 · 30 participants
- efficacy and safety of 0.5 mg fingolimod in patients with primary progressive multiple sclerosis: A study to evaluate how safe and effective 0.5 mg FTY720 is in delaying disability progression if taken once daily, in patients with PPMS
MSProgressive MSPhase 3Terminated
fingolimod · Novartis Pharma Services AG · 2012 · 700 participants
- FUMAPMS: Treatment with dimethyl fumarate in patients with primary progressive multiple sclerosis
MSProgressive MSPhase 2Completed
dimethyl fumarate · Finn Sellebjerg · 2016 · 54 participants
About this data
Where the data comes from
ClinicalTrials.gov, the EU Clinical Trials Register, ISRCTN, ChEMBL and Europe PMC, combined into the MSFrontier trial bank.
How it is collected
Registry records are collected automatically, duplicate records across registries are merged, and treatments, phases and populations are tagged by software from the registry data. When an error is reported, we fix the rule so the fix applies to every trial, and log it in the Corrections log.
Last update
Trial bank updated recently. Sources and corrections
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error